These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23388840)

  • 41. Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.
    Wang L; Shi WY; Wu ZY; Varna M; Wang AH; Zhou L; Chen L; Shen ZX; Lu H; Zhao WL; Janin A
    J Hematol Oncol; 2010 Sep; 3():30. PubMed ID: 20828385
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
    Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
    Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.
    Raymond E; Alexandre J; Faivre S; Vera K; Materman E; Boni J; Leister C; Korth-Bradley J; Hanauske A; Armand JP
    J Clin Oncol; 2004 Jun; 22(12):2336-47. PubMed ID: 15136596
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor.
    Peuvrel L; Quéreux G; Brocard A; Saint-Jean M; Dréno B
    Dermatology; 2012; 224(3):204-8. PubMed ID: 22614575
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials.
    Iacovelli R; Palazzo A; Mezi S; Morano F; Naso G; Cortesi E
    Acta Oncol; 2012 Sep; 51(7):873-9. PubMed ID: 22909392
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.
    De Masson A; Fouchard N; Méry-Bossard L; Dauendorffer JN
    Dermatology; 2011; 223(1):4-8. PubMed ID: 21846963
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.
    Buckner JC; Forouzesh B; Erlichman C; Hidalgo M; Boni JP; Dukart G; Berkenblit A; Rowinsky EK
    Invest New Drugs; 2010 Jun; 28(3):334-42. PubMed ID: 19415181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mantle cell lymphoma: the promise of new treatment options.
    Goy A; Kahl B
    Crit Rev Oncol Hematol; 2011 Oct; 80(1):69-86. PubMed ID: 21168343
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
    Fujisaka Y; Yamada Y; Yamamoto N; Horiike A; Tamura T
    Jpn J Clin Oncol; 2010 Aug; 40(8):732-8. PubMed ID: 20430774
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
    Habermann TM; Lossos IS; Justice G; Vose JM; Wiernik PH; McBride K; Wride K; Ervin-Haynes A; Takeshita K; Pietronigro D; Zeldis JB; Tuscano JM
    Br J Haematol; 2009 May; 145(3):344-9. PubMed ID: 19245430
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current status of targeted therapies for mantle cell lymphoma.
    Chang JE; Kahl BS
    Drugs; 2011 Dec; 71(17):2307-26. PubMed ID: 22085387
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Temsirolimus.
    Ma WW; Jimeno A
    Drugs Today (Barc); 2007 Oct; 43(10):659-69. PubMed ID: 17987219
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma.
    Haritunians T; Mori A; O'Kelly J; Luong QT; Giles FJ; Koeffler HP
    Leukemia; 2007 Feb; 21(2):333-9. PubMed ID: 17136116
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.
    O'Connor OA; Portlock C; Moskowitz C; Straus D; Hamlin P; Stubblefield M; Dumetrescu O; Colevas AD; Grant B; Zelenetz A
    Br J Haematol; 2008 Oct; 143(2):201-9. PubMed ID: 18691173
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells.
    Hipp S; Ringshausen I; Oelsner M; Bogner C; Peschel C; Decker T
    Haematologica; 2005 Oct; 90(10):1433-4. PubMed ID: 16219581
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.
    Peng L; Zhou Y; Ye X; Zhao Q
    Tumour Biol; 2015 Feb; 36(2):643-54. PubMed ID: 25281033
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Practical management of everolimus-related toxicities in patients with advanced solid tumors.
    Grünwald V; Weikert S; Pavel ME; Hörsch D; Lüftner D; Janni W; Geberth M; Weber MM
    Onkologie; 2013; 36(5):295-302. PubMed ID: 23689226
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus.
    Moosburner M; Alibegovic L; Hasselmann K; Gaiderov A; Hildebrand J; Philippou-Massier J; Blum H; Fischer L; Dreyling M; Silkenstedt E
    Hematol Oncol; 2023 Dec; 41(5):858-868. PubMed ID: 37300279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.